Korean company aims for 10 billion won in sales with highly accurate blood-based dementia diagnosis kit

Quantamatrix, a manufacturer of diagnostic and testing products, sells Alzheimer's Plus, a blood test that can diagnose dementia. The company is targeting the Korean Alzheimer's disease diagnostic market at about 200 billion won.
The company estimates that sales will reach 21.077 billion yen (approximately JPY 21.077 billion), and hopes to achieve sales of more than 10 billion won (approximately JPY 1.05347 billion) within the next three years.
AlzPlus is unique in that it can classify everything from normal conditions to subjective cognitive decline, mild cognitive impairment, and Alzheimer's disease.
This is because the patient has four biomarkers, including ARMYroid beta and angiotensin converting enzyme. The results of cognitive function tests conducted at hospitals and those of ARTZ Plus are highly significant.
It is also likely that this technology will be able to provide data necessary for not only early detection of Alzheimer's, but also for brain health management, and is expected to become an essential diagnostic method in the medical field in the future.
The company's strategy is to build a system that can handle all stages of dementia, from early detection to treatment and prevention. It is currently partnering with various medical facilities to provide guides on prevention and management necessary after detection.
CEO Kwon SungHoon said, "We aim to introduce this system to large health checkup centers within the first half of the year."